| Drug 1 | |
| Generic/Working Name | Crizotinib |
| Trade Name | Xalkori |
| Company Name | Pfizer Inc. |
| Drug Type | Small molecule |
| Drug Class | ALK inhibitor |
| Dose | 250 milligrams (mg) per flat dose |
| Route | Oral (p.o.) |
| Schedule of Administration | Dose level 0: 250 mg twice daily in combination with pembrolizumab |
| Drug 2 | |
| Generic/Working Name | Pembrolizumab |
| Trade Name | Keytruda |
| Company Name | Merck Sharp & Dohme |
| Drug Type | Monoclonal antibody |
| Drug Class | Programmed death receptor‐1 (PD‐1 blocking antibody) |
| Dose | 200 milligrams (mg) per flat dose |
| Route | IV |
| Schedule of Administration | Dose level 0: 200 mg every 3 weeks in combination with crizotinib |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.